{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:38:58Z","timestamp":1792219138891,"version":"4.4.0"},"reference-count":85,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":247,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853995"],"award-info":[{"award-number":["853995"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2025,1,1]]},"DOI":"10.1016\/j.csbj.2025.09.008","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:27:58Z","timestamp":1757255278000},"page":"4007-4018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of shared and unique mechanisms of atopic dermatitis and ulcerative colitis by construction and computational analysis of disease maps"],"prefix":"10.34133","volume":"27","author":[{"given":"Oxana","family":"Lopata","sequence":"first","affiliation":[{"name":"Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio Luis","family":"Acencio","sequence":"additional","affiliation":[{"name":"Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Wang","sequence":"additional","affiliation":[{"name":"Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Abdelmonem","family":"Hemedan","sequence":"additional","affiliation":[{"name":"Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Chao","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Jelinsky","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany"},{"name":"Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Rosenstiel","sequence":"additional","affiliation":[{"name":"Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Y.F.","family":"Li Yim","sequence":"additional","affiliation":[{"name":"Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Schneider","sequence":"additional","affiliation":[{"name":"Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg"},{"name":"ELIXIR Luxembourg, Esch-sur-Alzette, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata","family":"Satagopam","sequence":"additional","affiliation":[{"name":"Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg"},{"name":"ELIXIR Luxembourg, Esch-sur-Alzette, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ostaszewski","sequence":"additional","affiliation":[{"name":"Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg"},{"name":"ELIXIR Luxembourg, Esch-sur-Alzette, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221115312","article-title":"Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations","volume":"15","author":"Bezzio C.","year":"2022","unstructured":"Bezzio C. et al: Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations. Ther Adv Gastroenterol 2022; 15. 17562848221115312.","journal-title":"Ther Adv Gastroenterol"},{"key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3899\/jrheum.110901","article-title":"Socioeconomic burden of immune-mediated inflammatory diseases--focusing on work productivity and disability","volume":"88","author":"Jacobs P.","year":"2011","unstructured":"Jacobs P., Bissonnette R. and Guenther L.C.: Socioeconomic burden of immune-mediated inflammatory diseases--focusing on work productivity and disability. J Rheumatol Suppl 2011; 88: 55.","journal-title":"J Rheumatol Suppl"},{"key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1007\/s12325-019-00964-z","article-title":"Risk of developing additional immune-mediated manifestations: a retrospective matched cohort study","volume":"36","author":"Aletaha D.","year":"2019","unstructured":"Aletaha D. et al: Risk of developing additional immune-mediated manifestations: a retrospective matched cohort study. Adv Ther 2019; 36: 1672.","journal-title":"Adv Ther"},{"key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","article-title":"Comorbidities of atopic dermatitis-what does the evidence say?","volume":"151","author":"Thyssen J.P.","year":"2023","unstructured":"Thyssen J.P., Halling A.-S., Schmid-Grendelmeier P., Guttman-Yassky E. and Silverberg J.I.: Comorbidities of atopic dermatitis-what does the evidence say?. J Allergy Clin Immunol 2023; 151: 1155.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jaad.2020.05.130","article-title":"Bidirectional relationship between atopic dermatitis and inflammatory bowel disease: a systematic review and meta-analysis","volume":"83","author":"Lee H.","year":"2020","unstructured":"Lee H., Lee J.H., Koh S.-J. and Park H.: Bidirectional relationship between atopic dermatitis and inflammatory bowel disease: a systematic review and meta-analysis. J Am Acad Dermatol 2020; 83: 1385.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_6_7_2","first-page":"699","article-title":"Ulcerative colitis","volume":"87","author":"Adams S.M.","year":"2013","unstructured":"Adams S.M. and Bornemann P.H.: Ulcerative colitis. Am Fam Physician 2013; 87: 699.","journal-title":"Am Fam Physician"},{"key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.20344\/amp.11963","article-title":"Update on atopic dermatitis","volume":"32","author":"Torres T.","year":"2019","unstructured":"Torres T. et al: Update on atopic dermatitis. Acta Med Port 2019; 32: 606.","journal-title":"Acta Med Port"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910661"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-019-00751-6"},{"key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/00365521.2023.2209688","article-title":"Atopic dermatitis is associated with the clinical course of inflammatory bowel disease","volume":"58","author":"Kim K.W.","year":"2023","unstructured":"Kim K.W. et al: Atopic dermatitis is associated with the clinical course of inflammatory bowel disease. Scand J Gastroenterol 2023; 58: 1115.","journal-title":"Scand J Gastroenterol"},{"key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaci.2022.03.030","article-title":"Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study","volume":"150","author":"de Lusignan S.","year":"2022","unstructured":"de Lusignan S. et al: Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study. J Allergy Clin Immunol 2022; 150: 709.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaci.2015.06.029","article-title":"Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes","volume":"137","author":"Schmitt J.","year":"2016","unstructured":"Schmitt J. et al: Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol 2016; 137: 130.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.0022-202X.2004.23462.x","article-title":"An association between ulcerative colitis and atopic dermatitis, diseases of impaired superficial barriers","volume":"123","author":"Niwa Y.","year":"2004","unstructured":"Niwa Y., Sumi H. and Akamatsu H.: An association between ulcerative colitis and atopic dermatitis, diseases of impaired superficial barriers. J Invest Dermatol 2004; 123: 999.","journal-title":"J Invest Dermatol"},{"key":"e_1_3_6_15_2","first-page":"2072","article-title":"Atopic diseases are associated with development of inflammatory bowel diseases in korea: a nationwide Population-based study","volume":"19","author":"Soh H.","year":"2021","unstructured":"Soh H. et al: Atopic diseases are associated with development of inflammatory bowel diseases in korea: a nationwide Population-based study. Clin Gastroenterol Hepatol Clin Pract J Am Gastroenterol Assoc 2021; 19: 2072.","journal-title":"Clin Gastroenterol Hepatol Clin Pract J Am Gastroenterol Assoc"},{"key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/ibd\/izab329","article-title":"Causal association between atopic dermatitis and inflammatory bowel disease: a 2-Sample bidirectional mendelian randomization study","volume":"28","author":"Meisinger C.","year":"2022","unstructured":"Meisinger C. and Freuer D.: Causal association between atopic dermatitis and inflammatory bowel disease: a 2-Sample bidirectional mendelian randomization study. Inflamm Bowel Dis 2022; 28: 1543.","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/1346-8138.16642","article-title":"Causal association between atopic eczema and inflammatory bowel disease: a two-sample bidirectional mendelian randomization study of the east asian population","volume":"50","author":"Wang L.","year":"2023","unstructured":"Wang L. et al: Causal association between atopic eczema and inflammatory bowel disease: a two-sample bidirectional mendelian randomization study of the east asian population. J Dermatol 2023; 50: 327.","journal-title":"J Dermatol"},{"key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41540-018-0059-y","article-title":"Systems Medicine disease maps: community-driven comprehensive representation of disease mechanisms","volume":"4","author":"Mazein A.","year":"2018","unstructured":"Mazein A. et al: Systems Medicine disease maps: community-driven comprehensive representation of disease mechanisms. NPJ Syst Biol Appl 2018; 4: 21.","journal-title":"NPJ Syst Biol Appl"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bby024"},{"key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"1197310","DOI":"10.3389\/fbinf.2023.1197310","article-title":"A guide for developing comprehensive systems biology maps of disease mechanisms: planning, construction and maintenance","volume":"3","author":"Mazein A.","year":"2023","unstructured":"Mazein A. et al: A guide for developing comprehensive systems biology maps of disease mechanisms: planning, construction and maintenance. Front Bioinforma 2023; 3: 1197310.","journal-title":"Front Bioinforma"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa840"},{"key":"e_1_3_6_22_2","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4565","article-title":"Exploration and comparison of molecular mechanisms across diseases using MINERVA net","volume":"32","author":"Gawron P.","year":"2023","unstructured":"Gawron P., Smula E., Schneider R. and Ostaszewski M.: Exploration and comparison of molecular mechanisms across diseases using MINERVA net. Protein Sci Publ Protein Soc 2023; 32: e4565.","journal-title":"Protein Sci Publ Protein Soc"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkm958"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr777"},{"key":"e_1_3_6_25_2","first-page":"1575","article-title":"Baricitinib: the first jak inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients","volume":"9","author":"Radi G.","year":"2021","unstructured":"Radi G. et al: Baricitinib: the first jak inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients. Healthc Basel Switz 2021; 9: 1575.","journal-title":"Healthc Basel Switz"},{"key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"2161812","DOI":"10.1080\/09546634.2022.2161812","article-title":"Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials","volume":"34","author":"Bieber T.","year":"2023","unstructured":"Bieber T. et al: Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatol Treat 2023; 34: 2161812.","journal-title":"J Dermatol Treat"},{"key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2217\/imt-2023-0057","article-title":"Abrocitinib for the treatment of atopic dermatitis","volume":"15","author":"L\u00e9 A.M.","year":"2023","unstructured":"L\u00e9 A.M., Gooderham M. and Torres T.: Abrocitinib for the treatment of atopic dermatitis. Immunotherapy 2023; 15: 1351.","journal-title":"Immunotherapy"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107723"},{"key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/gast.2001.29694","article-title":"Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging","volume":"121","author":"Gitter A.H.","year":"2001","unstructured":"Gitter A.H., Wullstein F., Fromm M. and Schulzke J.D.: Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001; 121: 1320.","journal-title":"Gastroenterology"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.04.004"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.09.023"},{"key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.imlet.2009.11.001","article-title":"IL-33 is upregulated in colonocytes of ulcerative colitis","volume":"128","author":"Seidelin J.B.","year":"2010","unstructured":"Seidelin J.B. et al: IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett 2010; 128: 80.","journal-title":"Immunol Lett"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2023.12.006"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.026"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1245"},{"key":"e_1_3_6_36_2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jid.2019.07.713","article-title":"Increased IL-26 expression promotes t helper type 17- and t helper type 2-Associated cytokine production by keratinocytes in atopic dermatitis","volume":"140","author":"Kamijo H.","year":"2020","unstructured":"Kamijo H. et al: Increased IL-26 expression promotes t helper type 17- and t helper type 2-Associated cytokine production by keratinocytes in atopic dermatitis. J Invest Dermatol 2020; 140: 636.","journal-title":"J Invest Dermatol"},{"key":"e_1_3_6_37_2","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.7150\/ijms.45765","article-title":"Rapamycin blocks the IL-13-induced deficiency of epidermal barrier related proteins via upregulation of miR-143 in HaCaT keratinocytes","volume":"17","author":"Jia Q.-N.","year":"2020","unstructured":"Jia Q.-N. and Zeng Y.-P.: Rapamycin blocks the IL-13-induced deficiency of epidermal barrier related proteins via upregulation of miR-143 in HaCaT keratinocytes. Int J Med Sci 2020; 17: 2087.","journal-title":"Int J Med Sci"},{"key":"e_1_3_6_38_2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaci.2012.12.1566","article-title":"Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin","volume":"131","author":"Pellerin L.","year":"2013","unstructured":"Pellerin L. et al: Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol 2013; 131: 1094.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.11.006"},{"key":"e_1_3_6_40_2","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.3389\/fimmu.2018.02983","article-title":"Effects of epithelial IL-13R\u03b12 expression in inflammatory bowel disease","volume":"9","author":"Verstockt B.","year":"2018","unstructured":"Verstockt B. et al: Effects of epithelial IL-13R\u03b12 expression in inflammatory bowel disease. Front Immunol 2018; 9: 2983.","journal-title":"Front Immunol"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2017.52"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.05.002"},{"key":"e_1_3_6_43_2","first-page":"97","article-title":"Pathogenesis of atopic dermatitis: current paradigm","volume":"16","author":"Furue M.","year":"2019","unstructured":"Furue M. et al: Pathogenesis of atopic dermatitis: current paradigm. Iran J Immunol IJI 2019; 16: 97.","journal-title":"Iran J Immunol IJI"},{"key":"e_1_3_6_44_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaci.2019.01.015","article-title":"Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis","volume":"144","author":"Zhou L.","year":"2019","unstructured":"Zhou L. et al: Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2019; 144: 144.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_6_45_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3892\/ijmm.2013.1287","article-title":"Aberrant expression of circulating Th17, Th1 and Tc1 cells in patients with active and inactive ulcerative colitis","volume":"31","author":"Dong Z.","year":"2013","unstructured":"Dong Z. et al: Aberrant expression of circulating Th17, Th1 and Tc1 cells in patients with active and inactive ulcerative colitis. Int J Mol Med 2013; 31: 989.","journal-title":"Int J Mol Med"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2920"},{"key":"e_1_3_6_47_2","first-page":"1849","article-title":"STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines","volume":"190","author":"Rosen M.J.","year":"2013","unstructured":"Rosen M.J. et al: STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines. J Immunol Baltim Md 1950 2013; 190: 1849.","journal-title":"J Immunol Baltim Md 1950"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200X.2009.03019.x"},{"key":"e_1_3_6_49_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109852","article-title":"Chlorophyll a and novel synthetic derivatives alleviate atopic dermatitis by suppressing Th2 cell differentiation via IL-4 receptor modulation","volume":"258","author":"Kang K.M.","year":"2024","unstructured":"Kang K.M. et al: Chlorophyll a and novel synthetic derivatives alleviate atopic dermatitis by suppressing Th2 cell differentiation via IL-4 receptor modulation. Clin Immunol Orlando Fla 2024; 258: 109852.","journal-title":"Clin Immunol Orlando Fla"},{"key":"e_1_3_6_50_2","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s10875-023-01530-7","article-title":"Autosomal dominant STAT6 gain of function causes severe atopy associated with lymphoma","volume":"43","author":"Minskaia E.","year":"2023","unstructured":"Minskaia E. et al: Autosomal dominant STAT6 gain of function causes severe atopy associated with lymphoma. J Clin Immunol 2023; 43: 1611.","journal-title":"J Clin Immunol"},{"key":"e_1_3_6_51_2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/intimm\/dxg062","article-title":"Persistent secretion of IL-18 in the skin contributes to IgE response in mice","volume":"15","author":"Nakano H.","year":"2003","unstructured":"Nakano H. et al: Persistent secretion of IL-18 in the skin contributes to IgE response in mice. Int Immunol 2003; 15: 611.","journal-title":"Int Immunol"},{"key":"e_1_3_6_52_2","first-page":"949","article-title":"FcepsilonRI engagement of langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro","volume":"113","author":"Novak N.","year":"2004","unstructured":"Novak N. et al: FcepsilonRI engagement of langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. J Allergy Clin Immunol 2004; 113: 949.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms161226172"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0602900103"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2015.13"},{"key":"e_1_3_6_56_2","first-page":"150","article-title":"Expression of interleukin 18 in intestinal mucosa of patients with inflammatory bowel disease and its implications","volume":"35","author":"Zhang B.","year":"2003","unstructured":"Zhang B. et al: Expression of interleukin 18 in intestinal mucosa of patients with inflammatory bowel disease and its implications. Beijing Da Xue Xue Bao 2003; 35: 150.","journal-title":"Beijing Da Xue Xue Bao"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.6.812"},{"key":"e_1_3_6_58_2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1365-2222.2005.02295.x","article-title":"Alpha-toxin is produced by skin colonizing staphylococcus aureus and induces a t helper type 1 response in atopic dermatitis","volume":"35","author":"Breuer K.","year":"2005","unstructured":"Breuer K. et al: Alpha-toxin is produced by skin colonizing staphylococcus aureus and induces a t helper type 1 response in atopic dermatitis. Clin Exp Allergy J Br Soc Allergy Clin Immunol 2005; 35: 1088.","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"e_1_3_6_59_2","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1007\/s10620-021-07300-y","article-title":"A new role for conivaptan in ulcerative colitis in mice: inhibiting differentiation of CD4+T cells into Th1 cells","volume":"67","author":"Dou D.","year":"2022","unstructured":"Dou D. et al: A new role for conivaptan in ulcerative colitis in mice: inhibiting differentiation of CD4+T cells into Th1 cells. Dig Dis Sci 2022; 67: 3683.","journal-title":"Dig Dis Sci"},{"key":"e_1_3_6_60_2","doi-asserted-by":"crossref","first-page":"7799","DOI":"10.1038\/s41598-018-26088-y","article-title":"Amelioration of experimental autoimmune encephalomyelitis and DSS induced colitis by NTG-A-009 through the inhibition of Th1 and Th17 cells differentiation","volume":"8","author":"Acharya S.","year":"2018","unstructured":"Acharya S. et al: Amelioration of experimental autoimmune encephalomyelitis and DSS induced colitis by NTG-A-009 through the inhibition of Th1 and Th17 cells differentiation. Sci Rep 2018; 8: 7799.","journal-title":"Sci Rep"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.026"},{"key":"e_1_3_6_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1540-2"},{"key":"e_1_3_6_63_2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/cea.13560","article-title":"Neuronal branching of sensory neurons is associated with BDNF-positive eosinophils in atopic dermatitis","volume":"50","author":"Guseva D.","year":"2020","unstructured":"Guseva D. et al: Neuronal branching of sensory neurons is associated with BDNF-positive eosinophils in atopic dermatitis. Clin Exp Allergy J Br Soc Allergy Clin Immunol 2020; 50: 577.","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy215"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.048"},{"key":"e_1_3_6_66_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00280.2022"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130351"},{"key":"e_1_3_6_68_2","article-title":"TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation","volume":"5","author":"Kim B.S.","year":"2013","unstructured":"Kim B.S. et al: TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 2013; 5. 170ra16.","journal-title":"Sci Transl Med"},{"key":"e_1_3_6_69_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000073716","article-title":"The interleukin-13 production by peripheral blood t cells from atopic dermatitis patients does not require CD2 costimulation","volume":"132","author":"Simon D.","year":"2003","unstructured":"Simon D., Von Gunten S., Borelli S., Braathen L.R. and Simon H.-U.: The interleukin-13 production by peripheral blood t cells from atopic dermatitis patients does not require CD2 costimulation. Int Arch Allergy Immunol 2003; 132: 148.","journal-title":"Int Arch Allergy Immunol"},{"key":"e_1_3_6_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00243-6"},{"key":"e_1_3_6_71_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161759","article-title":"Impaired tight junctions in atopic dermatitis skin and in a Skin-Equivalent model treated with Interleukin-17","volume":"11","author":"Yuki T.","year":"2016","unstructured":"Yuki T., Tobiishi M., Kusaka-Kikushima A., Ota Y. and Tokura Y.: Impaired tight junctions in atopic dermatitis skin and in a Skin-Equivalent model treated with Interleukin-17. PloS One 2016; 11: e0161759.","journal-title":"PloS One"},{"key":"e_1_3_6_72_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00461"},{"key":"e_1_3_6_73_2","first-page":"2383","article-title":"The TLR and IL-1 signalling network at a glance","volume":"127","author":"Cohen P.","year":"2014","unstructured":"Cohen P.: The TLR and IL-1 signalling network at a glance. J Cell Sci 2014; 127: 2383.","journal-title":"J Cell Sci"},{"key":"e_1_3_6_74_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.28.16514"},{"key":"e_1_3_6_75_2","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1093\/ibd\/izaa243","article-title":"Tofacitinib for the treatment of ulcerative colitis, alopecia universalis, and atopic dermatitis: one drug, three diseases","volume":"27","author":"Honap S.","year":"2021","unstructured":"Honap S., Cookson H., Sharma E., Samaan M.A. and Irving P.M.: Tofacitinib for the treatment of ulcerative colitis, alopecia universalis, and atopic dermatitis: one drug, three diseases. Inflamm Bowel Dis 2021; 27: e13.","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_3_6_76_2","first-page":"542","article-title":"Atopic dermatitis and ulcerative colitis successfully treated with upadacitinib","volume":"59","author":"Grieco T.","year":"2023","unstructured":"Grieco T. et al: Atopic dermatitis and ulcerative colitis successfully treated with upadacitinib. Med Kaunas Lith 2023; 59: 542.","journal-title":"Med Kaunas Lith"},{"key":"e_1_3_6_77_2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10787-023-01396-6","article-title":"Baricitinib relieves DSS-induced ulcerative colitis in mice by suppressing the NF-\u03baB and JAK2\/STAT3 signalling pathways","volume":"32","author":"Wu Q.","year":"2024","unstructured":"Wu Q. et al: Baricitinib relieves DSS-induced ulcerative colitis in mice by suppressing the NF-\u03baB and JAK2\/STAT3 signalling pathways. Inflammopharmacology 2024; 32: 849.","journal-title":"Inflammopharmacology"},{"key":"e_1_3_6_78_2","first-page":"1","article-title":"Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis","volume":"28","author":"Edwards S.J.","year":"2024","unstructured":"Edwards S.J. et al: Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. Health Technol Assess Winch Engl 2024; 28: 1.","journal-title":"Health Technol Assess Winch Engl"},{"key":"e_1_3_6_79_2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nbt.1558","article-title":"The systems biology graphical notation","volume":"27","author":"Le Nov\u00e8re N.","year":"2009","unstructured":"Le Nov\u00e8re N. et al: The systems biology graphical notation. Nat Biotechnol 2009; 27: 735.","journal-title":"Nat Biotechnol"},{"key":"e_1_3_6_80_2","doi-asserted-by":"crossref","first-page":"16020","DOI":"10.1038\/npjsba.2016.20","article-title":"MINERVA-a platform for visualization and curation of molecular interaction networks","volume":"2","author":"Gawron P.","year":"2016","unstructured":"Gawron P. et al: MINERVA-a platform for visualization and curation of molecular interaction networks. NPJ Syst Biol Appl 2016; 2: 16020.","journal-title":"NPJ Syst Biol Appl"},{"key":"e_1_3_6_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab1028"},{"key":"e_1_3_6_82_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.1.27"},{"key":"e_1_3_6_83_2","article-title":"Signalling maps in cancer research: construction and data analysis","author":"Kondratova M.","year":"2018","unstructured":"Kondratova M., Sompairac N., Barillot E., Zinovyev A. and Kuperstein I.: Signalling maps in cancer research: construction and data analysis. Database J Biol Databases Curation 2018 bay036 2018; .","journal-title":"Database J Biol Databases Curation 2018 bay036"},{"key":"e_1_3_6_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1478-5382(03)02370-9"},{"key":"e_1_3_6_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1128"},{"key":"e_1_3_6_86_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad1021"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037025003691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037025003691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2025.09.008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:35:09Z","timestamp":1775219709000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2025.09.008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":85,"alternative-id":["10.1016\/j.csbj.2025.09.008"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2025.09.008","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of shared and unique mechanisms of atopic dermatitis and ulcerative colitis by construction and computational analysis of disease maps","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2025.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}